Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myeloma bone disease.

N S Callander1, G D Roodman

  • 1Department of Medicine/Hematology, University of Texas Health Science Center, San Antonio, TX, USA.

Seminars in Hematology
|August 7, 2001
PubMed
Summary

Myeloma bone disease involves significant bone destruction due to osteoclast-activating factors (OAFs). Understanding these factors and utilizing advanced imaging and treatments offers new hope for managing myeloma bone complications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth.

Leukemia·2017
Same author

Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up.

Blood cancer journal·2016
Same author

Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen.

Blood cancer journal·2016
Same author

Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo.

Leukemia·2016
Same author

Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial.

Blood cancer journal·2016
Same author

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.

Bone marrow transplantation·2015

Area of Science:

  • Oncology
  • Bone Biology
  • Biochemistry

Background:

  • Bone destruction is a common and severe complication in multiple myeloma, affecting 70-80% of patients.
  • Myeloma bone disease is driven by osteoclast-activating factors (OAFs) produced by myeloma cells and the microenvironment.

Purpose of the Study:

  • To review the key osteoclast-activating factors (OAFs) involved in myeloma bone disease.
  • To discuss current and emerging diagnostic methods for evaluating myeloma bone disease.
  • To outline existing and potential therapeutic strategies for managing myeloma bone complications.

Main Methods:

  • Review of literature on myeloma bone disease pathogenesis, diagnosis, and treatment.
  • Identification of key osteoclast-activating factors (OAFs) such as macrophage inflammatory protein-1-alpha (MIP-1alpha) and RANK ligand (RANKL).
  • Summary of diagnostic imaging modalities including radiography, MRI, PET, Mibi, and DEXA scanning.

Main Results:

  • Multiple OAFs contribute to myeloma bone disease, with MIP-1alpha and RANKL being leading candidates.
  • IL-6, secreted by marrow stromal cells, promotes myeloma growth and may contribute to bone disease.
  • Advanced imaging techniques provide more comprehensive evaluation of bone involvement compared to plain radiographs.

Conclusions:

  • Understanding the pathogenesis of myeloma bone disease, including the role of OAFs, is crucial for developing effective treatments.
  • Multimodal diagnostic approaches enhance the assessment of bone involvement in myeloma patients.
  • Ongoing research into the pathogenesis and treatment of myeloma bone disease offers promising avenues for patient care.

Related Experiment Videos